CANTA Cantargia AB (publ)

0.1260USD1.280 SEK · STO+0.08%Mkt Cap: 31.32M USDP/E: 1.88

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind I…

Key Statistics

Company
Market Cap31.32M USD
Enterprise Value9.48M USD
Revenue (TTM)31.23M USD
Gross Profit31.23M USD
Net Income (TTM)14.47M USD
Revenue/Share0.13 USD
Last Price0.1260 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees22
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0006371126
Valuation
P/E (Trailing)1.88
P/E (Forward)-1.36
PEG—
EV/EBITDA0.57
EV/Revenue0.30
P/S1.00
P/B1.21
EPS (TTM)0.07 USD
EPS (Forward)-0.09 USD
52W Range
0.12301% of range0.6487
52W High0.6487 USD
52W Low0.1230 USD
Profitability
Gross Margin100.00%
Oper. Margin52.46%
EBITDA Margin53.13%
Profit Margin46.41%
ROE55.28%
ROA49.54%
ROIC—
ROCE57.89%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF14.78M USD
CapEx (TTM)46.46K USD
FCF Margin10.00%
FCF Yield9.98%
Net Debt-21.85M USD
Net Debt/EBITDA-1.32
Net Debt/FCF-6.99
Balance Sheet
Debt/Equity—
Current Ratio7.03
Quick Ratio6.93
Book Value/Sh0.10 USD
Cash/Share0.09 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)0.8120 USD
Upside (mean)+544.5%
Target Range0.4429 USD – 1.181 USD
0.4429+544.5% to mean1.181
# Analysts2
Ownership
Shares Out.248.61M
Float237.72M
Insiders9.47%
Institutions26.77%
Technical
SMA 500.1439 (-12.4%)
SMA 2000.2565 (-50.9%)
Beta1.66
S&P 52W Chg12.00%
Avg Vol (30d)1.47M
Avg Vol (10d)995.48K
Technical Indicators
RSI (14)35.1
MACD-0.0433
MACD Signal-0.0108
MACD Hist.-0.0325
BB Upper0.1756 USD
BB Middle0.1463 USD
BB Lower0.1171 USD
BB Width39.94%
ATR (14)0.0094 USD
Vol Ratio (20d)0.26x

About Cantargia (STO: CANTA)

›

Cantargia (STO: CANTA) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 22 employees.

The shares were at 1.280 SEK on 19 November 2026, down 64.6% over 52 weeks. Its 52-week range is 1.250 SEK to 6.590 SEK: the price is 80.6% below the high and 2.4% above the low.

At a market capitalisation of 318.22M SEK, it trades at 1.9 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a discount of 94% for CANTA.

Cantargia reports return on equity of 55.3% and an operating margin of 52.5%.

It holds more cash than debt, a net cash position of 221.96M SEK. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. The next earnings report is expected on 25 November 2026.